Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALNY 
Alnylam Pharmaceuticals Inc (ALNY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ALNY (3-star) is a STRONG-BUY. BUY since 92 days. Simulated Profits (63.34%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
33 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $442.44
1 Year Target Price $442.44
| 12 | Strong Buy |
| 12 | Buy |
| 7 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 47.36% | Avg. Invested days 30 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 60.46B USD | Price to earnings Ratio - | 1Y Target Price 442.44 |
Price to earnings Ratio - | 1Y Target Price 442.44 | ||
Volume (30-day avg) 33 | Beta 0.32 | 52 Weeks Range 205.87 - 484.21 | Updated Date 09/17/2025 |
52 Weeks Range 205.87 - 484.21 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.96% | Operating Margin (TTM) -2.09% |
Management Effectiveness
Return on Assets (TTM) -2.63% | Return on Equity (TTM) -257.83% |
Valuation
Trailing PE - | Forward PE 51.55 | Enterprise Value 58898363878 | Price to Sales(TTM) 24.56 |
Enterprise Value 58898363878 | Price to Sales(TTM) 24.56 | ||
Enterprise Value to Revenue 23.92 | Enterprise Value to EBITDA 204.85 | Shares Outstanding 131079000 | Shares Floating 126145201 |
Shares Outstanding 131079000 | Shares Floating 126145201 | ||
Percent Insiders 3.79 | Percent Institutions 99.06 |
Upturn AI SWOT
Alnylam Pharmaceuticals Inc
Company Overview
History and Background
Alnylam Pharmaceuticals, founded in 2002, pioneered RNA interference (RNAi) therapeutics. It has achieved significant milestones in developing and commercializing RNAi-based medicines for genetic diseases.
Core Business Areas
- RNAi Therapeutics: Focuses on developing and commercializing RNAi-based therapeutics for genetic diseases and other conditions.
- Rare Disease Focus: Addresses unmet medical needs in rare genetic diseases with limited treatment options.
Leadership and Structure
The leadership team includes the CEO, CFO, and other executives. The organizational structure involves research, development, and commercial operations divisions.
Top Products and Market Share
Key Offerings
- Estimated_Revenue: 675000000
- ONPATTRO (patisiran): An RNAi therapeutic for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). Competitors include Pfizer (VNDAQ) with Vyndaqel and Ionis Pharmaceuticals (IONS) with Tegsedi and Waylivra. ONPATTRO generated significant revenue for Alnylam in recent years.
- Estimated_Revenue: 175000000
- GIVLAARI (givosiran): An RNAi therapeutic for acute hepatic porphyria (AHP). Competitors include Recordati Rare Diseases with Panhematin. GIVLAARI continues to contribute to Alnylam's revenue growth.
- Estimated_Revenue: 125000000
- OXLUMO (lumasiran): An RNAi therapeutic for primary hyperoxaluria type 1 (PH1). Competitors are limited, but potential future gene therapies could provide competition.OXLUMO is a growing revenue source for Alnylam.
- AMVUTTRA (vutrisiran): An RNAi therapeutic for hereditary transthyretin-mediated amyloidosis (ATTRv) polyneuropathy. Intended as a successor to ONPATTRO. Primary competitors are the same as ONPATTRO: Pfizer (VNDAQ) and Ionis Pharmaceuticals (IONS)
- Estimated_Revenue: 300000000
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. RNAi therapeutics represent an innovative approach to drug development.
Positioning
Alnylam is a leader in RNAi therapeutics, with a strong pipeline and established commercial products. Their competitive advantage lies in their proprietary technology platform and expertise in RNAi.
Total Addressable Market (TAM)
The total addressable market for RNAi therapeutics is projected to be substantial, potentially reaching billions of dollars, as more indications are targeted. Alnylam is well-positioned to capture a significant share of this TAM.
Upturn SWOT Analysis
Strengths
- Pioneering RNAi technology platform
- Established commercial products
- Strong pipeline of drug candidates
- Expertise in RNAi delivery and development
Weaknesses
- High R&D expenses
- Reliance on a single technology platform
- Competition from other therapeutic modalities
- Regulatory and reimbursement challenges
Opportunities
- Expanding RNAi technology to new therapeutic areas
- Partnering with other pharmaceutical companies
- Developing next-generation RNAi therapies
- Addressing unmet medical needs in rare diseases
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Patent disputes
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- PFE
- IONS
Competitive Landscape
Alnylam has a competitive advantage in RNAi therapeutics. However, it faces competition from companies developing other modalities for treating the same diseases.
Growth Trajectory and Initiatives
Historical Growth: Alnylam has experienced rapid revenue growth driven by the commercialization of its RNAi therapeutics. However, profitability has been a challenge due to high R&D expenses.
Future Projections: Analyst estimates project continued revenue growth for Alnylam driven by new product launches and expanding market share. Profitability is expected to improve as revenue scales.
Recent Initiatives: Recent initiatives include expanding the pipeline, seeking regulatory approvals for new products, and establishing partnerships to broaden market reach.
Summary
Alnylam Pharmaceuticals is a leading company in the emerging field of RNAi therapeutics, showing strong revenue growth driven by its innovative products like ONPATTRO and GIVLAARI. Their strength lies in its proprietary technology and growing pipeline. However, the company must carefully manage high R&D expenditures and face increasing competition and regulatory hurdles. Potential risks include clinical trial failures and patent disputes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Alnylam Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alnylam Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2004-05-28 | CEO & Director Dr. Yvonne L. Greenstreet M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2230 | Website https://www.alnylam.com |
Full time employees 2230 | Website https://www.alnylam.com | ||
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.